Humanin Nanoparticles for Reducing Pathological Factors Characteristic of Age-Related Macular Degeneration.

Solanki A, Smalling R, Parola AH, Nathan I, Kasher R, Pathak Y, Sutariya V

Current drug delivery1 Jan 2019Cited by 14 (Europe PMC)

PMID30381074DOI10.2174/1567201815666181031163111PepBankPUB-30381074

Publisher page PubMedAsk about this study

Summary

BackgroundHumanin is a novel neuronal peptide that has displayed potential in the treatment of Alzheimer's Disease through the suppression of inflammatory IL-6 cytokine receptors. Such receptors are found throughout the body, including the eye, suggesting its other potential applications. Age-related Macular Degeneration (AMD) is the leading cause of blindness in the developing world. There is no cure for this disease, and current treatments have several negative side effects associated with them, making finding other treatment options desirable.ObjectiveIn this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.MethodsAGA-HNG was synthesized and encapsulated in chitosan Nanoparticles (NPs), which were then characterized for their size, Encapsulation Efficiency (EE), and drug release. Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells. The chitosan NPs exhibited similar anti-VEGF properties and oxidative protection as the free protein while exhibiting superior pharmaceutical characteristics including biocompatibility and drug release.ResultsDrug-loaded NPs exhibited a radius of 346nm with desirable pharmacokinetic properties including a stable surface charge (19.5 ± 3.7 mV) and steady drug release capacity. AGA-HNG showed great promise in mediating apoptosis in hypoxic cells. They were also able to significantly reduce VEGF expression in vitro with reduced cellular toxicity compared to the free drug.ConclusionThe ability of this drug delivery system to reduce retinal apoptosis with desirable pharmacokinetic and biocompatible properties makes this a promising therapeutic option for AMD.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

01LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome
In ARPE-19 cells, the humanin derivative AGA-HNG showed promise in mediating apoptosis in hypoxic cells.
In plain wordsIn lab-grown retinal cells, a humanin derivative showed promise in affecting cell death under low oxygen.
Peptide
Humanin
Outcome
Not applicableApoptosis in hypoxic cells
Study
n: not reported in source
ARPE-19 cells
Outcome group
Cell viability and death · Eye
Source sentences
Summary
AGA-HNG showed great promise in mediating apoptosis in hypoxic cells.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107403
02LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome
In ARPE-19 cells, AGA-HNG nanoparticles significantly reduced VEGF expression.
In plain wordsIn lab-grown retinal cells, nanoparticles with a humanin derivative lowered VEGF, a blood vessel growth signal.
Peptide
Humanin
Outcome
DecreaseVEGF expression
Study
n: not reported in source
ARPE-19 cells
Outcome group
Inflammation markers · Eye
Source sentences
Summary
They were also able to significantly reduce VEGF expression in vitro with reduced cellular toxicity compared to the free drug.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107404
03LabNot a test of Humanin aloneIn vitro (cells)Safety outcome
In ARPE-19 cells, AGA-HNG nanoparticles showed reduced cellular toxicity compared with the free drug.
In plain wordsIn lab-grown retinal cells, the nanoparticles were less toxic than the free humanin derivative.
Peptide
Humanin
Outcome
DecreaseCellular toxicity
Study
n: not reported in source
ARPE-19 cells
Comparator
Free drug
Outcome group
Adverse events · Eye
Source sentences
Summary
They were also able to significantly reduce VEGF expression in vitro with reduced cellular toxicity compared to the free drug.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107405
04LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome
In ARPE-19 cells, chitosan nanoparticles showed anti-VEGF properties and oxidative protection similar to the free protein.
In plain wordsIn lab-grown retinal cells, the nanoparticles lowered VEGF and protected against oxidative damage about as well as the free protein.
Peptide
Humanin
Outcome
No significant changeAnti-VEGF effect and oxidative protection versus free protein
Study
n: not reported in source
ARPE-19 cells
Comparator
Free protein
Outcome group
Inflammation markers · Eye
Source sentences
Summary
The chitosan NPs exhibited similar anti-VEGF properties and oxidative protection as the free protein
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107406
05LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome
In ARPE-19 cells, chitosan nanoparticles showed superior pharmaceutical characteristics, including biocompatibility and drug release, compared with the free protein.
In plain wordsIn lab-grown retinal cells, the nanoparticles showed better compatibility and drug release than the free protein.
Peptide
Humanin
Outcome
IncreaseBiocompatibility and drug release versus free protein
Study
n: not reported in source
ARPE-19 cells
Comparator
Free protein
Outcome group
Pharmacokinetics · Eye
Source sentences
Summary
The chitosan NPs exhibited similar anti-VEGF properties and oxidative protection as the free protein while exhibiting superior pharmaceutical characteristics including biocompatibility and drug release.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107407
06LabNot a test of Humanin aloneIn vitro (cell-free)Other
Chitosan nanoparticles loaded with the humanin derivative AGA-HNG had a radius of 346 nm and a stable surface charge of 19.5 mV.
In plain wordsNanoparticles loaded with a humanin derivative had a radius of 346 nm and a stable surface charge.
Peptide
Humanin
Outcome
Not applicableNanoparticle radius and surface charge
Study
n: not reported in source
Chitosan nanoparticles loaded with AGA-HNG
Outcome group
Pharmacokinetics · Eye
Measurements
Nanoparticle radius
346 nm
Drug-loaded NPs
Surface charge
19.5 mV
Drug-loaded NPs
Source sentences
Summary
Drug-loaded NPs exhibited a radius of 346nm with desirable pharmacokinetic properties including a stable surface charge (19.5 ± 3.7 mV) and steady drug release capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107401
07LabNot a test of Humanin aloneIn vitro (cell-free)Pharmacokinetics
Chitosan nanoparticles loaded with the humanin derivative AGA-HNG showed steady drug release capacity.
In plain wordsNanoparticles loaded with a humanin derivative released the drug steadily.
Peptide
Humanin
Outcome
Not applicableDrug release
Study
n: not reported in source
Chitosan nanoparticles loaded with AGA-HNG
Outcome group
Pharmacokinetics · Eye
Source sentences
Summary
Drug-loaded NPs exhibited a radius of 346nm with desirable pharmacokinetic properties including a stable surface charge (19.5 ± 3.7 mV) and steady drug release capacity.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
Summary · context
Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Show in the study text Report a problemFND-3038107402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.